维普中文期刊产品整合服务
54篇 您的检索式:作者名="Telli C"
    题名 作者 年代 出处 被引量
1Radical Innovation Across Nations:The Preeminence of Corporate Culture显示文摘TELLIS G J PRABHU J C CHANDY R K 2009Journal of Marketing2009,,73:1
2Learning environment profiles of Turkish secondary biology classrooms显示文摘P den Brok S Telli J Cakiroglu R Taconis C Tekkaya 2010Learning Environ Res2010,,13:1
3The incumbent'S curse? incumbency,size,and radical product innovation显示文摘Rajesh C Tellis G 2000Journal of Marketing2000,,64:1
4gemoval of sm&ll &nd middle molecules by convective techniques显示文摘Loc&telli F Difilippo 8 M&nzoni C 2000Nephrol Di&l Tmnspl&nt2000,15,2:1
5Economics of environmental policy in Turkey : A general equilibrium investigation of the economic evaluation of seetoral emission reduction policies for climate change 显示文摘TELLI C VOYVODA E YELDAN E 2008Journal of Policy Modeling2008,30,2:1
6The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia显示文摘Aris P Agouridis Vasilis Tsimihodimos Theodosios D Filippatos Andromachi A Dimitriou Costantinos C Tellis Moses S Elisaf Dimitri P Mikhailidis Alexandros D Tselepis 2011Expert Opinion on Pharmacotherapy2011,,17:1
7早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 2016中国全科医学2016,19,18:1
8A new method for the so d stale synthesis of tertacalcium phosphate 显示文摘Sargi Y Kizilyaui M Telli C 1997Journal of the European Ceramic Society1997,17,:1
9Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus 显示文摘Cota L O Aquino D R Franco G C Cortelli J R Cor telli S C Costa F O 2010J Clin Periodontol2010,37,:1
10Radical innovation across nations : the pre-eminence of corporate culture 显示文摘TELLIS G J PRABHU J C CHANDY R K 2009Journal of Mar keting2009,73,1:1
11Relative humidity sen-sors based on an environment-sensitive fluorophore in hydrogelfilms显示文摘Tellis J C Strulson C A Myers M M 2011Anal Chem2011,83,:1
12Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation andoxidative stress in subjects with hypercholesterolemia 显示文摘MOUTZOURI E LIBEROPOULOS E N TELLIS C C 2013Ather-osclerosis2013,231,1:1
13Additional studies on the dis- tribution of stresses during vertical compaction of gutta-per- cha in the root canal 显示文摘Telli C Gulkan P Raab W 1999Brit Dent J1999,187,1:1
14A critical review of marketing research on diffusion of new products 显示文摘Deepa C Tellis G J 2007Review of Marketing Research2007,,3:1
15Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay 显示文摘Telli C Serper A Dogan AL 1999J Endod1999,25,12:1
16Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay显示文摘Telli C Serper A Dogan A L 1999Journal of Endodontics1999,25,12:1
17Evaluation of the cytotoxicity of calcium phosphate root canal sealers by MTT assay 显示文摘Telli C Serper A Dogan AL 1999J Endod1999,25,12:1
18Stress analysis during root canal falling by vertical and lateral condensation procedures:a three -dimensional finite de- ment model of a maxillary canine tooth显示文摘Telli C Gtilkan P 1998Br Dent J1998,185,2:1
19The incumbent's curse? incumbency, size, and radical product innovation 显示文摘Resh C Tellis G 2000Journal of Marketing2000,64,1:1
20Urothelial cancer of bladder in young versus older adults: Clinical and pathological characteristics and outcomes 显示文摘Telli O Sarici H Ozgur B C 2014Kaohsi- ungJ Med Sci2014,30,9:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费